Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
July 02 2024 - 8:00AM
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology
company focused on developing and launching the first curative
targeted cell therapies designed specifically for patients with
autoimmune diseases, today announced that Steven Nichtberger, M.D.,
Chief Executive Officer, will participate in a fireside chat at the
Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024, at
1:00 p.m. ET.
A live webcast of the presentation will be available on the News
and Events section of the Company’s website at
www.cabalettabio.com. Replays will be available on the website for
30 days.
About Cabaletta BioCabaletta Bio (Nasdaq: CABA)
is a clinical-stage biotechnology company focused on the discovery
and development of engineered T cell therapies that have the
potential to provide a deep and durable, perhaps curative,
treatment for patients with autoimmune diseases. The CABA™ platform
encompasses two strategies: the CARTA (chimeric antigen receptor T
cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing
fully human CD19-CAR T, as the lead product candidate being
evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials
in systemic lupus erythematosus, myositis, systemic sclerosis and
generalized myasthenia gravis and in the RESET-PV™ sub-study within
the DesCAARTes™ clinical trial in pemphigus vulgaris, along with
the CAART (chimeric autoantibody receptor T cells) strategy, with
multiple clinical-stage candidates, including DSG3-CAART for
mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated
myasthenia gravis. The expanding CABA™ platform is designed to
develop potentially curative therapies that offer deep and durable
responses for patients with a broad range of autoimmune diseases.
Cabaletta Bio’s headquarters and labs are located in Philadelphia,
PA.
Contacts:
Anup MardaChief Financial Officerinvestors@cabalettabio.com
William GramigPrecision AQwilliam.gramig@precisionaq.com
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Aug 2023 to Aug 2024